The Current Cheaper weight loss drugs “gamechanger” for Canadians
10 snips
Dec 3, 2025 Dr. Sanjeev Sockalingam, a leading expert on obesity and GLP-1 medications, joins Paul Leinwand, a strategy consultant focused on how these drugs impact consumer behavior. They discuss the upcoming arrival of generic GLP-1s in Canada, which could drastically reduce costs and reshape how Canadians approach their health and spending. The conversation highlights shifts in consumer habits, including changes in grocery purchases and even dating, while addressing the stigma surrounding obesity treatments and the societal implications of these medications.
AI Snips
Chapters
Transcript
Episode notes
Personal Rapid Weight‑Loss Example
- A guest reported losing nearly 25 pounds in 16 weeks and fitting into old pants again.
- That personal experience illustrates rapid, tangible changes people report on GLP‑1s.
Medical Consensus Shifts On Obesity
- GLP‑1 drugs are recognized as valid chronic‑disease treatments and can be integrated with behavioural care.
- The WHO urging lower costs signals global momentum for broader access to obesity care.
Uptake High But Coverage Low
- Around one in seven to one in eight Canadians were on GLP‑1s last year, and uptake is rising.
- Most people still pay out of pocket because provincial coverage is minimal and costs are high.